Does a lack of physical activity explain the rheumatoid arthritis lipid profile?

Lipids in Health and Disease

Volumn 16, Issue 1, 2017, Pages

  AbouAssi, Hiba ^a   Connelly, Margery A ^b   Bateman, Lori A ^c   Tune, K Noelle ^c   Huebner, Janet L ^a   Kraus, Virginia B ^a   Winegar, Deborah A ^b   Otvos, James D ^b   Kraus, William E ^a   Huffman, Kim M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIPOSCIENCE INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Arthritis; Cardiovascular risk; Exercise; Inflammation; Lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR; LIPID; LIPOPROTEIN;

ABDOMINAL VISCERAL ADIPOSITY; ADULT; AGE; ARTHRALGIA; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISABILITY; DISEASE ACTIVITY; DYSLIPIDEMIA; EXERCISE; FEMALE; GENDER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL ACTIVITY; RHEUMATOID ARTHRITIS; WAIST CIRCUMFERENCE; AGED; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXERCISE; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 85012022735     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-017-0427-4     Document Type: Article

References (31)

1. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-32.
2. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17:286-92.
3. van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JM, Castro CM. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis. 2013;231:163-72.
4. Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2014;33(1):115-21.
5. Dessein PH, Joffe BI, Stanwix AE. Editorial: should we evaluate insulin sensitivity in rheumatoid arthritis? Semin Arthritis Rheum. 2005;35:5-7.
6. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, Stein CM. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58:2105-12.
7. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-7.
8. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53:2143-54.
9. Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep. 2015;15:497.
10. Chung CP, Oeser A, Raggi P, Sokka T, Pincus T, Solus JF, Linton MF, Fazio S, Stein CM. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1633-8.
11. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012;64:1828-37.
12. Connelly MA, Shalaurova I, Otvos JD. High-density lipoprotein and inflammation in cardiovascular disease. Transl Res. 2016;173:7-18.
13. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67:616-25.
14. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74:694-702.
15. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483-92.
16. AbouAssi H, Tune KN, Gilmore B, Bateman LA, McDaniel G, Muehlbauer M, Huebner JL, Hoenig HM, Kraus VB, St Clair EW, et al. Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. J Rheumatol. 2014;41(10):1974-9.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
18. Huffman KM, Pieper CF, Hall KS, St Clair EW, Kraus WE. Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis. Scand J Rheumatol. 2015;44:106-10.
19. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847-70.
20. Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol. 2013;42:169-75.
21. Halverstadt A, Phares DA, Wilund KR, Goldberg AP, Hagberg JM. Endurance exercise training raises high-density lipoprotein cholesterol and lowers small low-density lipoprotein and very low-density lipoprotein independent of body fat phenotypes in older men and women. Metabolism. 2007;56:444-50.
22. Pettee KK, Kriska AM, Johnson BD, Conroy MB, Mackey RH, Orchard TJ, Kuller LH. The relationship between physical activity and lipoprotein subclasses in postmenopausal women: the influence of hormone therapy. Menopause. 2007;14:115-22.
23. Sarzynski MA, Burton J, Rankinen T, Blair SN, Church TS, Despres JP, Hagberg JM, Landers-Ramos R, Leon AS, Mikus CR, et al. The effects of exercise on the lipoprotein subclass profile: a meta-analysis of 10 interventions. Atherosclerosis. 2015;243:364-72.
24. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17:594-603.
25. Adams SA, Wirth MD, Khan S, Murphy EA, Heiney SP, Davis LC, Davis B, Drayton RF, Hurley TG, Blair SN, Hebert JR. The association of C-reactive protein and physical activity among a church-based population of African Americans. Prev Med. 2015;77:137-40.
26. Hakkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum. 2001;44:515-22.
27. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol. 2009;21:599-603.
28. van den Ende CH, Breedveld FC, le Cessie S, Dijkmans BA, de Mug AW, Hazes JM. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2000;59:615-21.
29. Woods JA, Vieira VJ, Keylock KT. Exercise, inflammation, and innate immunity. Immunol Allergy Clin North Am. 2009;29:381-93.
30. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1503-7.
31. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis. 2009;68:868-72.